Sudha Priya Soundara Pandi has over 15 years of experience in cell and molecular biology which includes 10 years of ophthalmology research experience in both academic and industrial settings (manufacturing, biotech and big pharmaceutical industry). She completed her Ph.D. on microRNA in aging and Age-related macular degeneration (AMD) at Queen’s University Belfast, UK. She is a pioneer of retinal stem cells and the characterization of AMD in donor eyes at Aravind medical research foundation, India. She has successfully developed a novel progressive retinal degeneration with central sparing displays features of parafoveal geographic atrophy at the University of Southampton, UK. She established an ex vivo vitreous stability model for the evaluation of a new drug entity at Oxular Ltd, UK. Project led and management of preclinical animal model development and gene therapy target efficiency and safety studies at Novartis, UK. In addition to that she established microRNA profiling liver tissues at Queen’s University Belfast, UK, CRISPR-cas9 gene editing in kidney cells at King’s College London, UK. She also acquired experience and strong leadership qualities from working in the molecular diagnostics industry as a Senior validation scientist at Primer Design, UK. She led a 12-member team and successfully validated multiple products and brought them to the market by a shorter deadline during the transition of IVDD to IVDR. Along with research experience, she has been actively involved in the training and day-to-day management of Ph.D. students, fellow post-docs, and technicians on animal models as well as suprachoroidal delivery technique in ex vivo system and line management of validation scientists highlighting her abilities as a communicator, mentor, and team player. Over these years of research experience, she became proficient in various skill sets in in vitro, in vivo, ex vivo, and human sample processing.